Skip to content

Role of Phaltrikadi Kwath, Chandraprabha Vati and Nyogradhadi Churn in Type-II Diabetes

CLINICAL EVALUATION OF CHANDRAPRABHA VATI AND NYOGRADHADI CHURNA WITH PHALATRIKADI KWATH IN THE MANAGEMENT OF TYPE II DIABETES MELLITUS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/07/034550
Enrollment
100
Registered
2021-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Chandraprabha vati with Nyogradhadi CHurna and Phalatrikadi Kwath in Diabetes mellitus Type 2: 2 tablet(250mg each) of Chandraprabha Vati orally with 1 sachet of (6gm) Nyogradhaadi Chur

Sponsors

Government Post Graduate Ayurveda College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex aged between 30 to 65 years 2. Treatment naive patients or diagnosed patients of Type II Diabetes Mellitus taking oral hypoglycaemic drugs for 3. Patients having Glycosylated haemoglobin (HbA1c) >= 6.5%. 4. Willing and able to participate for 16 weeks

Exclusion criteria

Exclusion criteria: 1. Patients already diagnosed to be suffering from the complications of Diabetes Mellitus viz., diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, etc. 2. Patients suffering from brittle diabetes mellitus. 3. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 4. Patient with poorly controlled Hypertension ( > 160 / 100 mm Hg) 5. Symptomatic patient with clinical evidence of Heart failure. 6. Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.2 mg/dl), uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or other concurrent severe disease. 7. Pregnant / Lactating women. 8. Patient on steroids, oral contraceptive pills or oestrogen replacement therapy. 9. Alcoholics and/or drug abusers. 10. Patients with evidence of malignancy 11. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, etc.) 12. H/o hypersensitivity to any of the trial drugs or their ingredients. 13. Patients who have completed participation in any other clinical trial during the past six (06) months. 14. Any other condition which the P.I. thinks may jeopardize the study.

Design outcomes

Primary

MeasureTime frame
Change in Glycosylated haemoglobin (HbA1c %)Timepoint: 42 days

Secondary

MeasureTime frame
Change in Symptoms -Diabetes Symptoms Questionnaire (DSQ) Change in Blood sugar Fasting. (10-12 hrs after dinner) Change in Blood sugar Post -Prandial (100-120 minutes after breakfast) Change in the SF-36-Health Survey Score.Timepoint: 12 weeks

Countries

India

Contacts

Public ContactNirmal Kumar

Government Post Graduate Ayurveda College and Hospital

drnirmalkumar007@gmail.com9628281199

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026